Under the control of collection and collection, how should enterprises break through the transformation?

TextYana new round of national collection, network news flying, enterprises have been in the competition for varieties, this year, the national leadership has repeatedly stressed that the national collection as a reform entry point, health care system-related reforminto a stable periodThe normalization and institutionalization of national collection and collection has become a regular mode of operation, and the concerns of enterprises should not be limited to the collection of varietiesIf we don't focus on national gathering, where should we focus?In 2019, the national collection belongs to a new thing, we face the collection in the conservative, but also the trend, the winner is difficult to accept the "high-pressure" stage of national collection; The country is touching the stone across the river, the policy is not fixed, the enterprise anxiety, is the normthis year, the leadership has repeatedly stressed that the national collection as an entry point for reform, the health care system related reforms into a stable periodThe normalization and institutionalization of national collection and collection has become a regular mode of operation, and the concerns of enterprises should not be limited to the collection of varietiesif you stare at the collection of varieties, will inevitably wait for the policy of "whip", wanton beatingEntering the national collection catalog of varieties, will face a sharp price reduction, enterprises can not benefit, without entering the national collection catalog, but also foreshadowed the loss of a large number of marketsenterprises in the consideration of whether to enter the national collection catalog, like chicken ribs, "the pity of tasteless abandonment", in the national collection of severe pain struggle, drinktoze thirst, not as hard as the bottom of the kettle to draw wageslast year, Hengrui cut a large number of generic drug projects to strengthen the positioning of innovative pharmaceutical companiesAlthough its non-patent edifying business contributed 86% of its total revenue, while the innovative drug business accounted for only 14%, The strongman's determination to break his wrist strengthens the strategy of Hengrui's innovative pharmaceutical company"As of now, the original research drug that has been patented, the imitation has been copied, even if it is a long time away from the expiration of the patent of the drug, we have evaluated the value of its market is not high, " said Sun Yuan, chairman ofHengrui Pharmaceuticals, at the 11th China Pharmaceutical Entrepreneur Scientist Stakes ConferenceAs a result, Hengrui, measured in terms of the ratio of investment to output, believes that the value of the investment is not too great - Hengrui should put money in a more efficient place"
it is understood that Hengrui has called a number of general generic suprapharmaceutical projects, only innovative drugs and high-end genericdrugs with core values Hengrui Pharmaceuticals' transition to innovation has been reaped, and on June 20, 2020, Hengrui independently developed PD-1 inhibitor Carelli Zuma to receive approval from the State Drug Administration (NMPA) for treatment in the field of lung cancer and esophageal cancer the internationalization trend of China's pharmaceutical industry, "differentiated competition" is becoming more and more important for the development of pharmaceutical companies Instead of paying attention to the competitive collection varieties, it is better to comb the existing varieties and re-strategic layout national collection has become the norm, is in a certain rules, procedures under the orderly promotion, therefore, for the national centralized procurement forecast is particularly important, rather than guessing varieties study rules and make predictions It is very important for the acquisition of collecting intelligence, and the study of collection strategies, understanding the collection rules and predicting the results of the collection can help non-patent pharmaceutical enterprises to obtain a favorable position in collection but this is limited to non-patentpharmaceutical enterprises, from the global pharmaceutical enterprise development law, there are not many enterprises innovative drugs and non-patent drug strategy go hand in hand, to obtain a leading position non-patented pharmaceutical companies can do well Mylan, the world's largest generic pharmaceutical company, is a U.S.-based pharmaceutical company with a global portfolio of more than 7,500, with sales of $4.09 billion and $4.15 billion in North America and $4.15 billion in North America and Europe last year with the completion of this round of medical system reform top-level design, the future of China's non-patented drug national collection, is not a problem, but a problem of fast and slow therefore, for pharmaceutical enterprises how to study the country in depth, at least 5-10 years of long-term planning, for the long-term development of enterprises to form a stable strategy set to deal with, in or out to enter the collection means that corporate profits or will drop significantly, how to operate become swells, the core of the problem is to reduce costs and efficiency Need to reduce costs from research and development, raw materials, production, marketing, and the pharmaceutical industry labor costs accountford relatively high (1) The value of research and development of non-patent pharmaceutical enterprises
the national collection of non-patent pharmaceutical enterprises research and development challenges, especially the institute approved non-patented drugs, may be approved into the national collection catalog, enterprise profits significantly reduced, this is a challenge to the non-patent drug enterprises research and development value or change the research and development model Whether there is a more optimized solution to the cost of research and development of generic drugs may be an effective way , for example, to strengthen its strategic advantage simply with mergers and acquisitions, as the world's largest generic drug company In 2005, Teva acquired The Aveys for $7.4 billion, Barr Pharmaceuticals in 2008 for $7.5 billion, and In 2010, it completed a 3.63 billion euro acquisition of Germany's Ratiopharm (2) through self-built API enterprises or long-term strategic cooperation the competition of API is unusually fierce, there is no stable supply of RAW materials or low-cost raw materials, will not be able to win in the competition of non-patent pharmaceutical enterprises, especially in the face of national collection, non-patented pharmaceutical enterprises to reduce the cost of raw materials and maintain a stable supply, enterprises need to work in these two aspects of deep root (3) the value of marketers in non-patent drugs
from a short-term perspective, non-patent pharmaceutical enterprises, whether direct mode or agent pharmaceutical companies, marketing staff to a certain extent there is still a certain value, but the cost and personnel ratio need to be controlled Especially large varieties, intended to enter the national collection catalog, the need for conversion marketing model to reduce costs long-term perspective, the overall medical system and operating model close to Europe and the United States, non-patent pharmaceutical enterprises need to explore a low-cost and efficient operating model do not enter the collection, enterprises need to change the marketing model, but no matter how the conversion, can not fundamentally compete with national policy trends, the next decade and beyond, price reduction is a big trend, but also the future the national collection is the general trend, but focus on collection, do not pay attention to corporate strategic planning, the future will be plunged into a dead end.